November 30, 2015 4:30 pm
Published by Lea Scheppke
Dr. Dorrell is a scientist at the Lowy Medical Research Institute. He oversees collaborations with extramural researchers, establishes connections with outside researchers who can help with LMRI’s MacTel research, and provides feedback on intramural projects.
November 30, 2015 4:05 pm
Published by Lea Scheppke
Dr. Marin Gantner is a scientist at the Lowy Medical Research Institute. She heads LMRI’s metabolism research program. She is studying metabolism in the retina, and developing the tools to assess metabolism in MacTel retinas.
November 29, 2015 4:02 pm
Published by Lea Scheppke
Dr. Kevin Eade is a scientist at the Lowy Medical Research Institute. He is currently developing stem cell technologies to study the cells of the human retina from patients afflicted with Macular Telangiectasia type 2.
November 26, 2015 4:05 pm
Published by Lea Scheppke
Dr. Simone Tzaridis is a Postdoctoral Associate at the Lowy Medical Research Institute. Her main research focus is on multimodal... View Article
November 26, 2015 4:03 pm
Published by Lea Scheppke
Dr. Lea Scheppke is the Director of Scientific Communications at the Lowy Medical Research Institute. She facilitates communication between LMRI’s scientific investigators and oversees public communication.
November 25, 2015 4:01 pm
Published by Lea Scheppke
Jennifer Trombley is the Global Project Director of Clinical Trials at the Lowy Medical Research Institute. She has over 40 years of acute nursing care experience, plus extensive experience with translational research and clinical research coordination.
November 25, 2015 4:00 pm
Published by Lea Scheppke
Dr. Friedlander is the President of LMRI, Professor at TSRI, and Chief of Retina Services at the Scripps Clinic. He oversees a laboratory program that is focused on understanding basic mechanisms that regulate the growth of new blood vessels as well as cell-cell interactions that help maintain normal neuronal function in the retina. His laboratory is interested in “translational” research with the goal of identifying new therapies to treat retinal diseases, including Macular Telangiectasia type 2.
November 24, 2015 4:55 pm
Published by Lea Scheppke
Investigators:
Martin Friedlander
Marcus Fruttiger
Mark Gillies
Lois Smith
November 24, 2015 4:54 pm
Published by Lea Scheppke
Investigators:
Marcus Fruttiger
Mark Gillies
LMRI
Martin Friedlander
November 24, 2015 4:52 pm
Published by Lea Scheppke
Investigators:
LMRI
Lois Smith
Mark Gillies
Marcus Fruttiger